Explore the latest news from Khondrion and its team.
Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness (MIDD) from European Commission...
Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the...
KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.
Khondrion receives €2.3M funding from EU Horizon 2020 SME instrument phase 2 program.
Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that its CEO Prof. dr. Jan Smeitink will present first results of Khondrion’s KHENERGY study at the Dutch Life Sciences Conference in Oss, The Netherlands, on November 22 at 10 am.
New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical...
Read the interview on pharmaboardroom.com Interview: Jan Smeitink – CEO, Khondrion, The Netherlands Jan Smeitink, CEO of...
Khondrion Welcomes Hans Schikan, Former Prosensa CEO, to Advisory Board August 10, 2015, NIJMEGEN – Khondrion, the Dutch...
